What is Emergent Biosolutions's cumulative cost basis?

Emergent Biosolutions (EBS) reported cumulative cost basis of $509.4M in Q1 2026.

How has Emergent Biosolutions's cumulative cost basis changed year-over-year?

Emergent Biosolutions's cumulative cost basis decreased by 1.6% year-over-year, from $517.8M to $509.4M.

What is the long-term trend for Emergent Biosolutions's cumulative cost basis?

Over 5 years (2020 to 2025), Emergent Biosolutions's cumulative cost basis has grown at a -10.8% compound annual growth rate (CAGR), from $903.2M to $509.5M.

Emergent Biosolutions EBS Cumulative Cost Basis

Cumulative Cost Basis at other companies

Regeneron PharmaceuticalsREGN

——

CorMedixCRMD

——

Collegium Pharmaceutical, Inc.COLL

——

West Pharmaceutical ServicesWST

——

Indivior Pharmaceuticals, Inc. INDV

——

Ginkgo BioworksDNA

——

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's cumulative cost basis?: Emergent Biosolutions (EBS) reported cumulative cost basis of $509.4M in Q1 2026.
How has Emergent Biosolutions's cumulative cost basis changed year-over-year?: Emergent Biosolutions's cumulative cost basis decreased by 1.6% year-over-year, from $517.8M to $509.4M.
What is the long-term trend for Emergent Biosolutions's cumulative cost basis?: Over 5 years (2020 to 2025), Emergent Biosolutions's cumulative cost basis has grown at a -10.8% compound annual growth rate (CAGR), from $903.2M to $509.5M.